苍耳亭
| 中文名称 | 苍耳亭 |
|---|---|
| 中文同义词 | 苍耳亭(标准品);苍耳亭;苍耳亭(反式);苍耳亭对照品;(3AR,7S,8AS)-7-甲基-3-亚甲基-6-((E)-3-氧代丁-1-烯-1-基)-3,3A,4,7,8,8A-六氢 2H-环庚并[B]呋喃-2-酮;顺式苍耳亭 |
| 英文名称 | xanthatin |
| 英文同义词 | 2H-Cyclohepta[b]furan-2-one,3,3a,4,7,8,8a-hexahydro-7-Methyl-3-Methylene-6-(3-oxo-1-buten-1-yl)-,(3aR,7S,8aS)-;(3aR)-3,3aα,4,7,8,8aβ-Hexahydro-7β-methyl-3-methylene-6-(3-oxo-1-butenyl)-2H-cyclohepta[b]furan-2-one;(3aR)-3-Methylene-7β-methyl-6-(3-oxo-1-butenyl)-3,3aα,4,7,8,8aβ-hexahydro-2H-cyclohepta[b]furan-2-one;2H-Cyclohepta[b]furan-2-one, 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-[(1E)-3-oxo-1-buten-1-yl]-, (3aR,7S,8aS)-;(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(E)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one;( - ) - xanthatin;(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(1E)-3-oxobut-1-en-1-yl]-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one;(3aR,7S,8aS)-7-Methyl-3-methylene-6-((E)-3-oxobut-1-en-1-yl)-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one |
| CAS号 | 26791-73-1 |
| 分子式 | C15H18O3 |
| 分子量 | 246.3 |
| EINECS号 | |
| 相关类别 | 标准品;植物提取物;对照品;中药对照品;精细化工;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;倍半萜;标准品 -中药标准品;标准品，对照品;独家化合物;化工衍生物;倍半萜内酯;standardized herbal extract |
| Mol文件 | 26791-73-1.mol |
| 结构式 |  |
苍耳亭 性质
| 熔点 | 114.5-115° |
|---|---|
| 比旋光度 | D30 -20° (ethanol) |
| 储存条件 | 2-8°C |
| 沸点 | 444.3±45.0 °C(Predicted) |
| 密度 | 1.10±0.1 g/cm3(Predicted) |
苍耳亭（标准品）用于含量测定、鉴别、药理实验、活性筛选等。
抗菌、消炎作用、祛风散热,除湿解毒。苍耳子的毒性源于其富含的倍半帖内酯类化合物,这类 成分常含有α,β不饱和y内酯结构,是其生物活性的一个主要基团。研究表明，从苍耳属(Xanthium L.)植物(如苍耳 子)中提取得到的倍半黏内酯化合物苍耳亭( Xanthatin),在 体内外实验中均显示出较强的抗肿瘤活性,其对非小细胞肺 癌的生长存在显著的抑制作用,且对正常肺上皮细胞生长影响较小。
Xanthatin 从 Xanthium strumarium 叶子中提取，诱导细胞凋亡 (apoptosis)。Xanthatin 通过抑制 PGE2 的合成和 5-脂氧合酶的活性而显示出抗炎活性。Xanthatin 抑制布鲁氏菌的 IC50 值为 2.63 μg/ mL，对寄生虫特异性锥虫硫磷还原酶具有不可逆的弱抑制作用。IC50: apoptosis; 3.8 μM (VEGFR2 kinase); 2.63 µg/mL ( T. b. brucei )
Xanthatin is against T. b. brucei with an IC 50 value of 2.63 µg/mL and exhibits weak irreversible inhibition of parasite specific trypanothione reductase.Xanthatin (0-40 μM; 24 hours) has obscure inhibition effect on the proliferation of HUVEC in the absence of VEGF.Xanthatin (5-40 μM; 24 hours) inhibits breast cancer cell proliferation in a dose responsive manner. Xanthatin inhibits HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 with IC 50 values of 81 μM, 31 μM, 38 μM, 30 μM, and 17 μM, respectively.Xanthatin (0-10 μM; 24 hours) dose dependently suppresses the phosphorylation of STAT3 (Ser727), at the same time, it also results in a rapid dephosphorylation of down-stream kinases of STAT3, including PI3K and Akt, including PI3K (p-PI3K p85 tyr458 ) and Akt.
Cell Proliferation Assay
| Cell Line: | HUVEC cells |
| Concentration: | 0 μM, 5 μM, 10 μM, 15 μM, 20 μM, 30 μM, 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited cell growth from dose 10 μM in the presence of vEGF. |
Cell Viability Assay
| Cell Line: | HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 cells |
| Concentration: | 5, 10, 15, 20, 30, and 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited breast cancer cell growth. |
Western Blot Analysis
| Cell Line: | HUVEC cells |
| Concentration: | 0, 3, and 10 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited VEGFR2 downstream signaling pathways and blocked VEGF-induced STAT3 activation in HUVEC. |
Xanthatin (intragastric administration; 20 mg/kg; once daily; 25 days) leads to significant inhibition of tumor volume. And this compound is well-tolerated and exhibits no significant difference in weight compares to the vehicle group.
| Animal Model: | Transplanted MDA-MB-231 cells into mice and constucted human breast cancer xenograft mouse model |
| Dosage: | 20 mg/kg; once daily; 25 days |
| Administration: | Intragastric administration |
| Result: | Supressed tumor growth and tumor angiogenesis in vivo. |
药理药效:抗菌、消炎作用。